NICE recommends semaglutide 2.4 mg (Wegovy) for eligible adults with obesity, and tirzepatide (Mounjaro) has received MHRA marketing authorisation
This personalization helps your medical team understand your individual medication metabolism, which informs how quickly your system clears GLP-1 and refines pre- and post-operative timing recommendations
What this means for your CGM data: Because GLP-1 drugs slow gastric emptying, they blunt the sharp post-meal glucose spikes that are hardest for insulin to catch
No, Ozempic is not recommended for those who are pregnant, trying to conceive, or breastfeeding
Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D., for the SURMOUNT-1 Investigators* Relevant Literature SURMOUNT-1 Trial Relevant Guidelines -SURMOUNT-1 Trial Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guidelines (2015) Drugs may amplify adherence to behavior change and improve physical functioning such that increased physical activity is easier for those who cannot exercise initially